Whilst a stagiaire at the Court of Justice of European Union, Jack worked on cases including: Kadi II (the effect of European procedural rights), Pringle (the validity of the European Stability Mechanism), Abdulrahim (continuing interest to bring an action for annulment), and Inuit I (the definition
of regulatory acts in Article 263 TFEU for the purposes of standing).
Although it is relatively clear that the Seal Traders are acting against a legislative act that in the eyes of trias politica could not be struck down lightly, the Court wanders into the realm
of the regulatory act by carefully picking its path.
Not exact matches
Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability
of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost
of accommodating, announced increases in the build rates
of certain aircraft; 6) the effect on aircraft demand and build rates
of changing customer preferences for business aircraft, including the effect
of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result
of global economic uncertainty or otherwise; 8) the effect
of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution
of key milestones such as the receipt
of necessary
regulatory approvals, including our ability to obtain in a timely fashion any required
regulatory or other third party approvals for the consummation
of our announced acquisition
of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability
of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk
of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production
of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or
acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak
of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact
of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition
of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect
of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices
Act and the United Kingdom Bribery
Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect
of changes in tax law, such as the effect
of The Tax Cuts and Jobs
Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations
of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect
of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability
of raw materials and purchased components; 23) our ability to recruit and retain a critical mass
of highly - skilled employees and our relationships with the unions representing many
of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment
of interest on, and principal
of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness
of any interest rate hedging programs; 28) the effectiveness
of our internal control over financial reporting; 29) the outcome or impact
of ongoing or future litigation, claims, and
regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition
of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result
of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks
of doing business internationally, including fluctuations in foreign current exchange rates, impositions
of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.
However this consideration is not within the scope
of Port Metro Vancouver's
regulatory mandate, nor should it be unduly influenced by local activists motivated by the maxim to think globally and
act locally.
Republicans view Cordray's position as the sole figurehead atop an enforcement agency created by the Dodd - Frank
Act as the symbol
of postrecession
regulatory overreach under President Barack Obama.
The other piece
of the Fix Crowdfunding
Act (H.R. 4855) that passed the House last night gives entrepreneurs a longer runway before having to deal with the
regulatory burden
of extensive, pre-IPO documents required to be filed with the SEC.
You see that Orphan Drug
Act (and a confluence
of other factors as well, both
regulatory and economic) helped set the stage for the Wild West marketplace we have now, in which gun - slinging drug makers can charge into town and charge whatever the heck they want for their wares.
That roadmap included using
regulatory authority under the less - restrictive Section 706
of the Telecommunications
Act, he says.
Such risks, uncertainties and other factors include, without limitation: (1) the effect
of economic conditions in the industries and markets in which United Technologies and Rockwell Collins operate in the U.S. and globally and any changes therein, including financial market conditions, fluctuations in commodity prices, interest rates and foreign currency exchange rates, levels
of end market demand in construction and in both the commercial and defense segments
of the aerospace industry, levels
of air travel, financial condition
of commercial airlines, the impact
of weather conditions and natural disasters and the financial condition
of our customers and suppliers; (2) challenges in the development, production, delivery, support, performance and realization
of the anticipated benefits
of advanced technologies and new products and services; (3) the scope, nature, impact or timing
of acquisition and divestiture or restructuring activity, including the pending acquisition
of Rockwell Collins, including among other things integration
of acquired businesses into United Technologies» existing businesses and realization
of synergies and opportunities for growth and innovation; (4) future timing and levels
of indebtedness, including indebtedness expected to be incurred by United Technologies in connection with the pending Rockwell Collins acquisition, and capital spending and research and development spending, including in connection with the pending Rockwell Collins acquisition; (5) future availability
of credit and factors that may affect such availability, including credit market conditions and our capital structure; (6) the timing and scope
of future repurchases
of United Technologies» common stock, which may be suspended at any time due to various factors, including market conditions and the level
of other investing activities and uses
of cash, including in connection with the proposed acquisition
of Rockwell; (7) delays and disruption in delivery
of materials and services from suppliers; (8) company and customer - directed cost reduction efforts and restructuring costs and savings and other consequences thereof; (9) new business and investment opportunities; (10) our ability to realize the intended benefits
of organizational changes; (11) the anticipated benefits
of diversification and balance
of operations across product lines, regions and industries; (12) the outcome
of legal proceedings, investigations and other contingencies; (13) pension plan assumptions and future contributions; (14) the impact
of the negotiation
of collective bargaining agreements and labor disputes; (15) the effect
of changes in political conditions in the U.S. and other countries in which United Technologies and Rockwell Collins operate, including the effect
of changes in U.S. trade policies or the U.K.'s pending withdrawal from the EU, on general market conditions, global trade policies and currency exchange rates in the near term and beyond; (16) the effect
of changes in tax (including U.S. tax reform enacted on December 22, 2017, which is commonly referred to as the Tax Cuts and Jobs
Act of 2017), environmental,
regulatory (including among other things import / export) and other laws and regulations in the U.S. and other countries in which United Technologies and Rockwell Collins operate; (17) the ability
of United Technologies and Rockwell Collins to receive the required
regulatory approvals (and the risk that such approvals may result in the imposition
of conditions that could adversely affect the combined company or the expected benefits
of the merger) and to satisfy the other conditions to the closing
of the pending acquisition on a timely basis or at all; (18) the occurrence
of events that may give rise to a right
of one or both
of United Technologies or Rockwell Collins to terminate the merger agreement, including in circumstances that might require Rockwell Collins to pay a termination fee
of $ 695 million to United Technologies or $ 50 million
of expense reimbursement; (19) negative effects
of the announcement or the completion
of the merger on the market price
of United Technologies» and / or Rockwell Collins» common stock and / or on their respective financial performance; (20) risks related to Rockwell Collins and United Technologies being restricted in their operation
of their businesses while the merger agreement is in effect; (21) risks relating to the value
of the United Technologies» shares to be issued in connection with the pending Rockwell acquisition, significant merger costs and / or unknown liabilities; (22) risks associated with third party contracts containing consent and / or other provisions that may be triggered by the Rockwell merger agreement; (23) risks associated with merger - related litigation or appraisal proceedings; and (24) the ability
of United Technologies and Rockwell Collins, or the combined company, to retain and hire key personnel.
Among the grab bag
of goodies in the pharma - backed 21st Century Cures
Act, which is meant to hasten FDA drug approvals, is a provision that would essentially remove the agency from the mobile health app and electronic medical records
regulatory process.
Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward - looking statements include, among others, the following: our ability to successfully and profitably market our products and services; the acceptance
of our products and services by patients and healthcare providers; our ability to meet demand for our products and services; the willingness
of health insurance companies and other payers to cover Cologuard and adequately reimburse us for our performance
of the Cologuard test; the amount and nature
of competition from other cancer screening and diagnostic products and services; the effects
of the adoption, modification or repeal
of any healthcare reform law, rule, order, interpretation or policy; the effects
of changes in pricing, coverage and reimbursement for our products and services, including without limitation as a result
of the Protecting Access to Medicare
Act of 2014; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain
regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis
of Financial Condition and Results
of Operations sections
of our most recently filed Annual Report on Form 10 - K and our subsequently filed Quarterly Reports on Form 10 - Q.
It drew mutual fund managers with independent streaks who simply wanted to opt out
of the
regulatory constraints imposed by the Investment Company
Act.
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount
of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability
of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction
of generic versions
of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care
Act or other government action that could have the effect
of lowering prices or reducing the number
of insured patients; the possibility
of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels
of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits
of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive
regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages
of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development
of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate
of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
You shall not be bound by the provisions
of confidentiality contained in this Agreement if such Holdings Information 1) is or becomes publicly known through no
act or omission
of the Financial Institution, its employees, agents or subcontractors; 2) is lawfully disclosed to you by a third party without restriction and without any obligation
of confidentiality; 3) is required to be disclosed by any Governmental body,
regulatory body (including without limitation any relevant securities exchange) or court
of competent jurisdiction or otherwise pursuant to any statutory or
regulatory obligation.
However, the
act of purchasing digital assets, including bitcoin, would remain legal under the proposed updates to the country's
regulatory code.
Title II
of the Jumpstart Our Business Startups
Act (JOBS
Act), which went into effect today, has lifted the ban on «general solicitation»
of investments by companies that rely on a widely used
regulatory exemption to issue securities.
If anyone doubted that he was serious about imposing this new level
of federal oversight on top
of the already crowded provincial
regulatory scene, signals coming from Flaherty's top officials this past summer suggested, not just a readiness to
act alone, but a growing enthusiasm for that option.
Any securities described herein may not be registered under the Securities
Act or with any securities
regulatory authority
of any state or other jurisdiction and may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities
Act pursuant to the terms
of such securities.
Such risks and uncertainties include, but are not limited to: our ability to achieve our financial, strategic and operational plans or initiatives; our ability to predict and manage medical costs and price effectively and develop and maintain good relationships with physicians, hospitals and other health care providers; the impact
of modifications to our operations and processes; our ability to identify potential strategic acquisitions or transactions and realize the expected benefits
of such transactions, including with respect to the Merger; the substantial level
of government regulation over our business and the potential effects
of new laws or regulations or changes in existing laws or regulations; the outcome
of litigation,
regulatory audits, investigations, actions and / or guaranty fund assessments; uncertainties surrounding participation in government - sponsored programs such as Medicare; the effectiveness and security
of our information technology and other business systems; unfavorable industry, economic or political conditions, including foreign currency movements;
acts of war, terrorism, natural disasters or pandemics; our ability to obtain shareholder or
regulatory approvals required for the Merger or the requirement to accept conditions that could reduce the anticipated benefits
of the Merger as a condition to obtaining
regulatory approvals; a longer time than anticipated to consummate the proposed Merger; problems regarding the successful integration
of the businesses
of Express Scripts and Cigna; unexpected costs regarding the proposed Merger; diversion
of management's attention from ongoing business operations and opportunities during the pendency
of the Merger; potential litigation associated with the proposed Merger; the ability to retain key personnel; the availability
of financing, including relating to the proposed Merger; effects on the businesses as a result
of uncertainty surrounding the proposed Merger; as well as more specific risks and uncertainties discussed in our most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section
of www.cigna.com as well as on Express Scripts» most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section
of www.express-scripts.com.
The Committee was established under the Dodd - Frank Wall Street Reform and Consumer Protection
Act to advise the Commission on
regulatory priorities, regulation
of securities products, trading strategies, fee structures, disclosure effectiveness, and initiatives to protect investors and promote investor confidence and the integrity
of the U.S. securities markets.
«Approval
of the rule change under Section 19b - 4
of the Exchange
Act of 1934 is usually the last
regulatory step for an active ETF to launch,» Ignites reported.
As part
of an investor protection measure in the JOBS
Act, companies using crowdfunding will still be required to raise the money through regulated broker - dealers, such as CircleUp, or through crowdfunding portals, a new
regulatory category at the SEC.
Referring to the decision, a spokesman for Sweden's Financial Supervisory Authority said that «every institution must decide on the details
of their internal regulations specifying the rules for their employees» investments and trading,» suggesting that the
regulatory agency does not intend to interfere in Nordea's decision, nor
act against similar moves that may be taken by other companies.
Whether you need an experienced attorney to handle the legal and
regulatory process
of a JOBS
Act offering, or a «quarterback» handle the details and the big picture every step
of the way, Kendall Almerico has the experience and knowledge to help create equity crowdfunding success.
The
act seeks to establish a foundation for virtual currency businesses by providing individual states with a common
regulatory guide for issues such as licensing requirements; reciprocity; consumer protection; cybersecurity; anti-money laundering; and supervision
of licensees.
The EEZ
Act was enacted in 2013 to provide a
regulatory framework to manage the environmental effects
of offshore resource development such as oil exploration and seabed mining.
WASHINGTON, D.C. — U.S. Chamber President and CEO Thomas J. Donohue issued the following statement today in response to U.S. Senate passage
of S. 2155, the «Economic Growth,
Regulatory Relief, and Consumer Protection
Act,» which will alleviate
regulatory burdens for America's local and community banks:
Actual results may vary materially from those expressed or implied by forward - looking statements based on a number
of factors, including, without limitation: (1) risks related to the consummation
of the Merger, including the risks that (a) the Merger may not be consummated within the anticipated time period, or at all, (b) the parties may fail to obtain shareholder approval
of the Merger Agreement, (c) the parties may fail to secure the termination or expiration
of any waiting period applicable under the HSR
Act, (d) other conditions to the consummation
of the Merger under the Merger Agreement may not be satisfied, (e) all or part
of Arby's financing may not become available, and (f) the significant limitations on remedies contained in the Merger Agreement may limit or entirely prevent BWW from specifically enforcing Arby's obligations under the Merger Agreement or recovering damages for any breach by Arby's; (2) the effects that any termination
of the Merger Agreement may have on BWW or its business, including the risks that (a) BWW's stock price may decline significantly if the Merger is not completed, (b) the Merger Agreement may be terminated in circumstances requiring BWW to pay Arby's a termination fee
of $ 74 million, or (c) the circumstances
of the termination, including the possible imposition
of a 12 - month tail period during which the termination fee could be payable upon certain subsequent transactions, may have a chilling effect on alternatives to the Merger; (3) the effects that the announcement or pendency
of the Merger may have on BWW and its business, including the risks that as a result (a) BWW's business, operating results or stock price may suffer, (b) BWW's current plans and operations may be disrupted, (c) BWW's ability to retain or recruit key employees may be adversely affected, (d) BWW's business relationships (including, customers, franchisees and suppliers) may be adversely affected, or (e) BWW's management's or employees» attention may be diverted from other important matters; (4) the effect
of limitations that the Merger Agreement places on BWW's ability to operate its business, return capital to shareholders or engage in alternative transactions; (5) the nature, cost and outcome
of pending and future litigation and other legal proceedings, including any such proceedings related to the Merger and instituted against BWW and others; (6) the risk that the Merger and related transactions may involve unexpected costs, liabilities or delays; (7) other economic, business, competitive, legal,
regulatory, and / or tax factors; and (8) other factors described under the heading «Risk Factors» in Part I, Item 1A
of BWW's Annual Report on Form 10 - K for the fiscal year ended December 25, 2016, as updated or supplemented by subsequent reports that BWW has filed or files with the SEC.
After the Real Estate (Regulation and Development)
Act, 2016 (the «
Act») was partially implemented in May 2016, it was incumbent on the states to draw up the rules for their respective states for carrying out the purpose
of the
Act and establishing the
regulatory authority.
«A truck driver has to be 100 % engaged in the
act of driving, scanning the horizon for that SUV that's changing a tire on the shoulder or some idiot doing something dumb, and anything less isn't something I want to deal with, ever,» says Scott Grenerth,
regulatory affairs director for the Owner - Operator Independent Drivers Association.
Additionally, Newsome led the CFTC's
regulatory implementation
of the Commodity Futures Modernization
Act of 2000 (CFMA).
This article, the second in a three - part series, focuses on the panel discussions
of ’40
Act fund structures and
regulatory concerns with liquid alternative funds.
The second article will discuss the SEC's use
of administrative proceedings to try enforcement cases, the impact
of the Dodd - Frank
Act's whistleblower program and guidance for managers on approaching a
regulatory exam or investigation.
However, companies should be aware
of the
regulatory and legal landscape so that they may proactively
act to avoid future civil and criminal liabilities.
NEW YORK, NY, October 9, 2017 — Despite widespread criticism regarding the heightened
regulatory environment that has pervaded since the introduction
of the Dodd - Frank Wall Street Reform and Consumer Protection
Act, as well as the Trump administration's promises to scale back regulations, the alternative investment industry doesn't foresee any lessening
of current regulations or regulators»...
Examples
of these risks, uncertainties and other factors include, but are not limited to the impact
of: adverse general economic and related factors, such as fluctuating or increasing levels
of unemployment, underemployment and the volatility
of fuel prices, declines in the securities and real estate markets, and perceptions
of these conditions that decrease the level
of disposable income
of consumers or consumer confidence; adverse events impacting the security
of travel, such as terrorist
acts, armed conflict and threats thereof,
acts of piracy, and other international events; the risks and increased costs associated with operating internationally; our expansion into and investments in new markets; breaches in data security or other disturbances to our information technology and other networks; the spread
of epidemics and viral outbreaks; adverse incidents involving cruise ships; changes in fuel prices and / or other cruise operating costs; any impairment
of our tradenames or goodwill; our hedging strategies; our inability to obtain adequate insurance coverage; our substantial indebtedness, including the ability to raise additional capital to fund our operations, and to generate the necessary amount
of cash to service our existing debt; restrictions in the agreements governing our indebtedness that limit our flexibility in operating our business; the significant portion
of our assets pledged as collateral under our existing debt agreements and the ability
of our creditors to accelerate the repayment
of our indebtedness; volatility and disruptions in the global credit and financial markets, which may adversely affect our ability to borrow and could increase our counterparty credit risks, including those under our credit facilities, derivatives, contingent obligations, insurance contracts and new ship progress payment guarantees; fluctuations in foreign currency exchange rates; overcapacity in key markets or globally; our inability to recruit or retain qualified personnel or the loss
of key personnel; future changes relating to how external distribution channels sell and market our cruises; our reliance on third parties to provide hotel management services to certain ships and certain other services; delays in our shipbuilding program and ship repairs, maintenance and refurbishments; future increases in the price
of, or major changes or reduction in, commercial airline services; seasonal variations in passenger fare rates and occupancy levels at different times
of the year; our ability to keep pace with developments in technology; amendments to our collective bargaining agreements for crew members and other employee relation issues; the continued availability
of attractive port destinations; pending or threatened litigation, investigations and enforcement actions; changes involving the tax and environmental
regulatory regimes in which we operate; and other factors set forth under «Risk Factors» in our most recently filed Annual Report on Form 10 - K and subsequent filings by the Company with the Securities and Exchange Commission.
Such
regulatory «protective guidelines,» as they are often called, offer to society false assurances
of control and
act as the honey (if you will) that helps the hemlock go down.
The National Environmental Policy
Act (NEPA) and the Plant Protection
Act (PPA) provide a robust
regulatory framework that ensures the protection
of the environment and the vital economic interests
of U.S. farmers.
«This
act gives the FDA a mandate for
regulatory oversight
of food safety systems that scientifically address hazards, and that puts great emphasis on preventing — rather than reacting to — food - borne illnesses,» Waters explains.
Engaging efforts with experts from 47 IDFA member companies and cooperation from other parts
of the dairy industry, the Food and Drug Administration (FDA) and state regulators, IDFA advocated for, among other things: reasonable regulations in the Pasteurized Milk Ordinance (PMO) that align the Interstate Milk Shippers program with the requirements
of the Food Safety Modernization
Act's (FSMA) Preventive Controls for Human Food (PCHF) rule; harmonizing the PMO with an FDA rule on higher fortification levels
of vitamin D3 and requiring FDA to be more transparent in the determination
of foreign country
regulatory equivalence with the U.S. Grade «A» program.
Unconscionable conduct (agrees with NFF that they have not provided protection and support reforms «to provide transparency in the supply chain» and recognise that «certain classes
of suppliers... are predisposed to suffering from a special disadvantage...»; misuse
of market power (legal framework must «level the balance
of market power in negotiations...», «ensure transparency in the transmission
of market prices» and «not allow for final market risks to be borne by the primary producer» and provide «transparency
of contract processes» - specifically, Canegrowers supports effects test and a process giving ACCC greater power to «regulate anti-competitive behaviour and impose penalties», shifting «the decisions framework from the judicial system to a
regulatory system» which would make it more accessible to small producers); collective bargaining (notes limits
of Sugar Industry
Act (Qld); authorisation and notification approval costly and limited and not a viable alternative - peak bodies should be able to «commence and progress collective bargaining with mills on behalf
of their members» and current threshold too restrictive)» competitive neutrality (mixed outcomes - perverse outcomes in the case
of natural monopolies - suggest remove «application
of competitive neutrality provisions to natural monopoly essential services»)
We are happy to report in response to a lawsuit filed against the Commonwealth's
regulatory use
of priority habitat screening to protect endangered species, the Massachusetts Supreme Judicial Court has ruled unanimously to affirm the state's authority under the Massachusetts Endangered Species
Act (MESA).
This ASTM safety standard was included by the US Consumer Product Safety Commission as part
of the mandatory
regulatory requirements issued under Section 104
of the Consumer Product Safety Improvement
Act.
Marking the first anniversary
of the Government's moratorium from new domestic regulation for micro businesses, the FSB has published a report which argues that the
Regulatory Policy Committee (RPC) needs more powers to scrutinise performance, advocate
regulatory reform and
act as an ombudsman.
Small correction: When ATF was moved to the Department
of Justice, under the Homeland Security
Act of 2002, its law enforcement and
regulatory functions were split.
«Enforcement works best when
regulatory agencies work together and we are honored to partner with Tax and Finance and the SLA to put a stop to the sale
of untaxed cigarettes,» said Gaming Commission
Acting Executive Director Ron Ochrym.
This is because the Supreme Court has ruled that, when a grant
of regulatory authority «lay [s] down by legislative
act an intelligible principle to which the person or body authorized to [
act] is directed to conform», Congress is not unconstitutionally delegating its ability to make laws.
The
acting state inspector general's office released a report earlier this morning that found workers for the state Public Service Commission received $ 7,000 worth
of meals and golf from entities under its
regulatory authority.
While this
act [Harrison Narcotics] is often seen as the start
of prohibition, the
act itself was not actually a prohibition on cocaine, but instead set up a
regulatory and licensing regime.
The
regulatory rollback by Republicans moved forward as lawmakers also inched closer to a bipartisan agreement to alter portions
of the 2010 Dodd - Frank
Act.